Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy.
Long ChenFengying LiaoZhongyong JiangChi ZhangZiwen WangPeng LuoQingzhi JiangJie WuQing WangMin LuoXueru LiYu LengLe MaGufang ShenZelin ChenYu WangXu TanYibo GanDengqun LiuYunsheng LiuChunmeng ShiPublished in: British journal of pharmacology (2020)
Metformin may be a radiotherapy adjuvant agent for colorectal cancers especially those carrying P53 mutation. Our findings provide a new strategy for further precise clinical trials for metformin on radiotherapy.